Patients with primary sclerosing cholangitis with and without end-stage liver disease have similar outcomes after liver transplantation
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F26%3A10001441" target="_blank" >RIV/00064190:_____/26:10001441 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.4254/wjh.v18.i3.112934" target="_blank" >https://doi.org/10.4254/wjh.v18.i3.112934</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.4254/wjh.v18.i3.112934" target="_blank" >10.4254/wjh.v18.i3.112934</a>
Alternative languages
Result language
angličtina
Original language name
Patients with primary sclerosing cholangitis with and without end-stage liver disease have similar outcomes after liver transplantation
Original language description
BACKGROUND Liver transplantation (LT) is the most effective treatment for the advanced stages of primary sclerosing cholangitis (PSC). However, up to 30% of patients develop recurrence of PSC (rPSC), which negatively affects graft and patient outcomes. Given the heterogeneous nature of PSC, patients undergo LT either due to end-stage liver disease (ESLD) or to symptoms that significantly reduce quality of life (non-ESLD), such as recurrent bacterial cholangitis or refractory pruritus. However, it remains unclear whether these indicators influence post-LT outcomes. AIM To compare post-LT outcomes between PSC recipients with ESLD and non-ESLD indications, and identify rPSC and graft failure risk factors. METHODS This single-center retrospective study comprised 131 adult LT recipients for PSC (including PSC/autoimmune overlap). Patients were grouped by listing indication for comparison of ESLD vs non-ESLD. ESLD was defined as model for ESLD score >= 15 and Child-Pugh score >= 8, or >= 1 sign of decompensated cirrhosis. Time-to-event outcomes were analyzed using Kaplan-Meier and Cox models with time-updated covariates. RESULTS No significant difference was found in the incidence of rPSC, graft survival, or overall survival between patients indicated for LT for ESLD and those with non-advanced symptomatic disease. Cytomegalovirus infection (hazard ratio [HR] = 2.16; 95% confidence interval [CI]: 1.05-4.46), acute cellular rejection (ACR) (HR = 3.95; 95%CI: 1.44-10.8), and length of hospitalization after LT (HR = 1.02; 95%CI: 1.01-1.04) were significantly associated with risk of rPSC. In addition, multiple episodes of ACR (HR = 4.93; 95%CI: 1.22-19.9) and the length of hospitalization after LT (HR = 1.04; 95%CI: 1.01-1.06) were significantly associated with graft failure. CONCLUSION Patients with PSC with advanced liver cirrhosis before LT did not have worse post-transplant outcomes than those without ESLD. Cytomegalovirus infection, ACR, and prolonged hospitalization after LT were associated with worse outcomes after LT in PSC.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30219 - Gastroenterology and hepatology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2026
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
World Journal of Hepatology
ISSN
1948-5182
e-ISSN
—
Volume of the periodical
18
Issue of the periodical within the volume
3
Country of publishing house
US - UNITED STATES
Number of pages
12
Pages from-to
nestránkováno
UT code for WoS article
001732559500007
EID of the result in the Scopus database
2-s2.0-105037580808